Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
| Website: | www.intersectent.com |
| Email: | ir@intersectENT.com |
| Main Phone: | +1 650 641-2100 |
| Address: | 1555 Adams Drive |
| State: | CA |
| City / Town: | Menlo Park |
| Country: | USA |
| Postal Code: | 94025 |
| Exchange: | NSD |
| CEO: | Thomas A. West |
| Employees: | 402 |
| NAICS: | Surgical and Medical Instrument Manufacturing(339112) |
Look for multiline and specialty retailers and providers of healthcare services to continue to pace this market (Image: Barron's).
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies
Intersect ENT (XENT) is a commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. It is headquartered in Menlo Park,
Full IPO calendar & reports HERE. The follow list is in order of largest IPO first. (1) Based in Luxembourg, Orion Engineered Carbons S.a r.l. (OEC) scheduled a $315 million IPO on
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
| Website: | www.intersectent.com |
| Email: | ir@intersectENT.com |
| Main Phone: | +1 650 641-2100 |
| Address: | 1555 Adams Drive |
| State: | CA |
| City / Town: | Menlo Park |
| Country: | USA |
| Postal Code: | 94025 |
| Exchange: | NSD |
| CEO: | Thomas A. West |
| Employees: | 402 |
| NAICS: | Surgical and Medical Instrument Manufacturing(339112) |
Look for multiline and specialty retailers and providers of healthcare services to continue to pace this market (Image: Barron's).
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies
Intersect ENT (XENT) is a commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. It is headquartered in Menlo Park,
Full IPO calendar & reports HERE. The follow list is in order of largest IPO first. (1) Based in Luxembourg, Orion Engineered Carbons S.a r.l. (OEC) scheduled a $315 million IPO on
| Last Price 13.73 | Change $ -0.22 | Change % -1.58 | Tick N/A |
| Bid 12.12 | Bid Size 100.00 | Ask 15.00 | Ask Size 300.00 |
| Open 14.23 | High 14.41 | Low 13.33 | Prev Close 13.95 |
| Last Trade | Volume 476,795 | 52 Wk Hi 31.46 | 52 Wk Low 5.97 |
| Market Cap 447 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 32,559,239.00 | EPS (TTM) -1.56 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 15 | 76 |
| Number of Buys | 10 | 35 |
| Number of Sells | 5 | 41 |
| Net Activity | 7570 | -141123 |
| Last 10 Buys | Shares |
|---|---|
| Kieran T. Gallahue | 1,000 |
| Kieran T. Gallahue | 1,000 |
| Cynthia L. Lucchese | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Jeryl L. Hilleman | 1,000 |
| Lisa E. Earnhardt | 1,000 |
| Jeryl L. Hilleman | 1,000 |
| Lisa E. Earnhardt | 1,000 |
| Jeryl L. Hilleman | 1,000 |
| Lisa E. Earnhardt | 1,000 |
| Jeryl L. Hilleman | 1,000 |
| Lisa E. Earnhardt | 1,000 |
| Jeryl L. Hilleman | 1,000 |
| Richard E. Kaufman | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 48 | 48 | 48 | 48 |
| Low Target Price Estimate | 32 | 32 | 32 | 32 |
| Mean Target Price Estimate | 42.71 | 42.71 | 42.71 | 42.71 |
| Standard Deviation | 5.94 | 5.94 | 5.94 | 5.94 |
| Date of Most Recent Estimate | 05/11/18 | 05/11/18 | 05/11/18 | 05/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-07 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.22 | 1.22 | 1.22 | 1.22 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait